Company: ERAS
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0000950170-25-042682
Chunk: 283

Company: Erasca, Inc.
Filing Date: 2025-03-20
Form: 10-K
Item: Item 6
Chunk 283
---
 )

    Maturities of marketable securities

    269,325

    244,945

    In-process research and development

    (22,500
    )

    (20,000
    )

    Payment made for investment in equity securities

    (157
    )

    —

    Purchases of property and equipment

    (60
    )

    (1,775
    )

    Net cash used in investing activities

    (156,616
    )

    (91,220
    )

    Cash flows from financing activities:

    Proceeds from issuance of common stock in private placement, net of fees and expenses

    43,604

    —

    Proceeds from issuance of common stock in underwritten offering, net of discounts and offering costs

    174,426

    —

    Proceeds from issuance of common stock in ATM Offering, net of commissions and expenses

    21,031

    —

    Proceeds from the exercise of stock options

    836

    505

    Proceeds from issuance of common stock under the Employee Stock Purchase Plan

    800

    790

    Net cash provided by financing activities

    240,697

    1,295

    Net decrease in cash, cash equivalents and restricted cash

    (25,336
    )

    (191,142
    )

    Cash, cash equivalents and restricted cash at beginning of the period

    93,483

    284,625

    Cash, cash equivalents and restricted cash at end of the period
     
    $
    68,147

    $
    93,483

    Supplemental disclosure of noncash investing and financing activities:

    Amounts accrued for purchases of property and equipment
     
    $
    —

    $
    13

    Vesting of early exercised options
     
    $
    465

    $
    1,231

The accompanying notes are an integral part of these consolidated financial statements.

 F-6

Erasca, Inc.

Notes to Consolidated Financial Statements

Note 1. Organization and basis of presentation  Organization and nature of operations Erasca, Inc. (Erasca or the Company) is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a RAS/MAPK pathway-focused pipeline comprising modality-